At the 2026 American Society of Clinical Oncology’s annual meeting, the latest results from the clinical trial investigating whether the drug, daraxonrasib can be effectively used as a treatment for late-stage pancreatic cancer were presented.
Researchers reported that the treatment could effectively double life expectancy for some patients with advanced pancreatic cancer.
Daraxonrasib works by blocking the activity of KRAS mutations in pancreatic cancer tumours, and has now been shown to improve survival in people with advanced pancreatic cancer. KRAS mutations are found in over 90% of all pancreatic tumours and are responsible for driving the growth of this devastating disease.
GCF Executive officer Liam Willis said of the findings..."The development of treatments targeting KRAS mutations (KRAS inhibitors) are some of the most exciting developments we have seen in pancreatic cancer for a long time"
"Tragically, around 85% of pancreatic cancer patients are diagnosed at an advanced stage, when curative treatments are not an option. These results suggest that daraxonrasib is able to keep the cancer under control for longer, giving patients priceless extra time with their loved ones."
At Gut Cancer Foundation we welcome this progress while recognising there is still much work to do. Daraxonrasib is not currently available in New Zealand and does not yet have Medsafe approval. We will be monitoring this exciting development closely, advocating on behalf of our community to ensure approval for use in New Zealand is sought as quickly as possible.
Read more here:
https://www.asco.org/about-asco/press-center/multi-selective-ras-inhibitor-nearly-doubles-survival-pancreatic-cancer
https://www.bbc.com/news/articles/cy82l435171o
https://www.oncologynewscentral.com/pancreatic-cancer/standing-ovation-at-asco-2026-for-grand-slam-pancreatic-cancer-data-daraxonrasib-doubles-survival